Randomized Controlled Study of the Safety and Immunogenicity of Pneumococcal Vaccine Formulations Containing PhtD and Detoxified Pneumolysin with Alum or Adjuvant System AS02 V in Elderly Adults

• Published in: Clinical and vaccine immunology Vol. 21; no. 5; pp. 651 - 660
• Main Authors: Pauksens, Karlis, Nilsson, Anna C., Caubet, Magalie, Pascal, Thierry G., Van Belle, Pascale, Poolman, Jan T., Vandepapelière, Pierre G., Verlant, Vincent, Vink, Peter E.
• Format: Journal Article
• Language: English
• Published: 01-05-2014
• ISSN: 1556-6811; 1556-679X
• DOI: 10.1128/CVI.00807-13

ABSTRACT
Six vaccine formulations containing AS02
V
or alum (aluminum phosphate [AlPO
4
]) adjuvant with pneumococcal proteins, pneumococcal histidine triad D (PhtD), and/or detoxified pneumolysin (dPly), either as a polysaccharide carrier in an 8-valent pneumococcal conjugate vaccine (8PCV) or as free (unconjugated) proteins, were evaluated in adults -65 to 85 years of age. In this phase I observer-blind study, 167 healthy subjects were randomized to receive two doses (days 0 and 60) of 10 or 30 μg PhtD-dPly plus AS02
V
or alum, 8PCV plus AS02
V
or alum, or one dose (day 0) of 23-valent polysaccharide pneumococcal vaccine (23PPV) as a control (placebo on day 60). The safety, reactogenicity, and antibody-specific responses to these vaccines were evaluated. No vaccine-related serious adverse events were reported. The incidences of solicited local and specific general (fatigue and myalgia) symptoms tended to be higher in the AS02
V
groups than in other groups. Anti-PhtD and anti-Ply antibody responses were observed in all groups except the control group. One month post-dose 2, the anti-PhtD and anti-Ply antibody geometric mean concentrations tended to be higher with AS02
V
than with alum, higher with a dose of 30 μg than with 10 μg for PhtD-dPly and higher with 30-μg PhtD-dPly formulations than with conjugated PhtD and dPly (8PCV) formulations. Functional antibody responses, measured by an opsonophagocytic activity assay, tended to be higher with 8PCV than with 23PPV. In conclusion, vaccine formulations containing free or conjugated PhtD and dPly had acceptable reactogenicity and safety profiles in elderly adults. Immune responses were enhanced with an AS02
V
-adjuvanted formulation containing free 30-μg PhtD-dPly compared to those with alum adjuvant and conjugated proteins. (This study has been registered at
ClinicalTrials.gov
under registration no. NCT00756067.)